Viewing Study NCT00358397



Ignite Creation Date: 2024-05-05 @ 4:57 PM
Last Modification Date: 2024-10-26 @ 9:26 AM
Study NCT ID: NCT00358397
Status: TERMINATED
Last Update Posted: 2016-10-14
First Post: 2006-07-27

Brief Title: One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Overview

Official Title: Phase I Safety Study of Clostridium Novyi-NT Spores in Patients With Treatment-Refractory Solid Tumor Malignancies
Status: TERMINATED
Status Verified Date: 2016-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Design Problem
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will include a one time intravenous IV infusion of Clostridium novyi-NT C novyi-NT spores to treat solid tumors which have not responded to standard therapy
Detailed Description: Investigators at the SKCCC have developed a bacterial strain C novyi-NT that can infect tumors and destroy them but does not grow in normal tissues In animal experiments a single intravenous injection of these bacteria can cause dramatic regression of many tumors and the tumors do not recur in approximately 30 of the animals

This is a phase I dose escalation study using a single dose of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies The overall objective of this study is to determine the safety and document any preliminary evidence of anti-tumor activity in this patient population

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None